The ERBB2 mRNA level was observably higher in the bladder, brain and CNS, breast, and pancreatic cancer tissues and signally lower in the colorectal, esophageal, head and neck, kidney, lung, lymphoma, and sarcoma cancers compared with the corresponding normal tissues. This evidence concerns the gene ERBB2 and lymphoma.